Damora TherapeuticsDMRA
13F holders, Q4 2024 (December 31)10holders
2new positions
3sold out
1famous investor
$4.65avg. 13F price*
At the end of Q4 2024, 10 institutions reported holding Damora Therapeutics Inc. (DMRA) in their 13F filings, unchanged from Q3 2024. 2 opened new positions and 3 sold out. The largest holders were Novo Holdings A/S ($465K), Renaissance Technologies ($70K) and Squarepoint Ops LLC ($59K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Damora Therapeutics Inc.
- Filed as
- GALECTO INC (Q4 2024)
- CUSIP
- 36322Q206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $60K |
| Exits | 3 | $4K |
All 13F filers, Q3 2024 → Q4 2024: 20,170 shares bought and 6,759 shares sold, net +13,411 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Novo Holdings A/S | 0.03% | No change | 99,913 | $465K |
| Renaissance Technologies | 0.00% | Reduce -29.6% | 15,044 | $70K |
| Squarepoint Ops LLC | 0.00% | New | 12,701 | $59K |
| UBS Group AG | 0.00% | Add +144.5% | 12,467 | $58K |
| Bank of America Corp. | 0.00% | Add +0.1% | 1,226 | $6K |
| BlackRock, Inc. | 0.00% | No change | 490 | $2K |
| JPMorgan Chase & Co. | 0.00% | New | 100 | $466 |
| Morgan Stanley | 0.00% | Reduce -37.5% | 100 | $465 |
| SBI Securities Co., Ltd. | 0.00% | — | 18 | $84 |
| Group One Trading LLC | 0.00% | No change | 3 | $14 |
"% of holder's portfolio" is DMRA's weight in each manager's 13F, not the share of Damora Therapeutics Inc. the manager owns.